SOLANA BEACH, Calif., Nov. 09, 2016 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ:EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced its financial results for the third quarter ended September 30, 2016.
Announced positive topline results from comparative exposure pharmacokinetic (PK) trial for Gimoti™ 505(b)(2) New Drug Application (NDA) submission on track for Q1 2018 filing Partnered with the Patheon division of Thermo Fisher Scientific Inc. as a commercial manufacturing partner for Gimoti
April 1, 2019 PDUFA date for Gimoti™ NDA Cash runway extended through June 2019 SOLANA BEACH, Calif. , Nov. 13, 2018 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced its financial
Gimoti NDA resubmission on track for fourth quarter 2019 SOLANA BEACH, Calif. , Nov. 07, 2019 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced its financial results for the third
Gimoti™ commercial launch underway SOLANA BEACH, Calif. , Nov. 10, 2020 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced its financial results for the third quarter ended September 30,
SOLANA BEACH, Calif. , Nov. 10, 2021 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases, today announced its financial results for the quarter ended September 30, 2021 and recent corporate
SOLANA BEACH, Calif., July 18, 2016 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ:EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced topline results from its Phase 3 clinical trial of EVK-001 in female patients with symptomatic
SOLANA BEACH, Calif. , June 27, 2019 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced that it has submitted a type A meeting request and meeting package to the U.S.